Literature DB >> 34155471

In Search of the SARS-CoV-2 Protection Correlate: Head-to-Head Comparison of Two Quantitative S1 Assays in Pre-characterized Oligo-/Asymptomatic Patients.

Raquel Rubio-Acero1, Noemi Castelletti1,2, Volker Fingerle3,4, Laura Olbrich1,3, Abhishek Bakuli1, Roman Wölfel3,5, Philipp Girl3,5, Katharina Müller3,5, Simon Jochum6, Matthias Strobl6, Michael Hoelscher1,3,7, Andreas Wieser1,3.   

Abstract

BACKGROUND: Quantitative serological assays detecting response to SARS-CoV-2 are needed to quantify immunity. This study analyzed the performance and correlation of two quantitative anti-S1 assays in oligo-/asymptomatic individuals from a population-based cohort.
METHODS: In total, 362 plasma samples (108 with reverse transcription-polymerase chain reaction [RT-PCR]-positive pharyngeal swabs, 111 negative controls, and 143 with positive serology without confirmation by RT-PCR) were tested with quantitative assays (Euroimmun Anti-SARS-CoV-2 QuantiVac enzyme-linked immunosorbent assay [EI-S1-IgG-quant]) and Roche Elecsys® Anti-SARS-CoV-2 S [Ro-RBD-Ig-quant]), which were compared with each other and confirmatory tests, including wild-type virus micro-neutralization (NT) and GenScript®cPass™. Square roots R of coefficients of determination were calculated for continuous variables and non-parametric tests were used for paired comparisons.
RESULTS: Quantitative anti-S1 serology correlated well with each other (true positives, 96%; true negatives, 97%). Antibody titers decreased over time (< 30 to > 240 days after initial positive RT-PCR). Agreement with GenScript-cPass was 96%/99% for true positives and true negatives, respectively, for Ro-RBD-Ig-quant and 93%/97% for EI-S1-IgG-quant. Ro-RBD-Ig-quant allowed distinct separation between positives and negatives, and less non-specific reactivity versus EI-S1-IgG-quant. Raw values (95% CI) ≥ 28.7 U/mL (22.6-36.4) for Ro-RBD-Ig-quant and ≥ 49.8 U/mL (43.4-57.1) for EI-S1-IgG-quant predicted NT > 1:5 in 95% of cases.
CONCLUSIONS: Our findings suggest both quantitative anti-S1 assays (EI-S1-IgG-quant and Ro-RBD-Ig-quant) may replace direct neutralization assays in quantitative measurement of immune protection against SARS-CoV-2 in certain circumstances. However, although the mean antibody titers for both assays tended to decrease over time, a higher proportion of Ro-RBD-Ig-quant values remained positive after 240 days. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40121-021-00475-x.
© The Author(s) 2021.

Entities:  

Keywords:  COVID-19; Direct virus neutralization assay S1; Quantitative serology; SARS-CoV-2

Year:  2021        PMID: 34155471     DOI: 10.1007/s40121-021-00475-x

Source DB:  PubMed          Journal:  Infect Dis Ther        ISSN: 2193-6382


  25 in total

1.  Results of the first pilot external quality assessment (EQA) scheme for anti-SARS-CoV2-antibody testing.

Authors:  Verena Haselmann; Mustafa K Özçürümez; Frank Klawonn; Volker Ast; Catharina Gerhards; Romy Eichner; Victor Costina; Gerhard Dobler; Wolf-Jochen Geilenkeuser; Roman Wölfel; Michael Neumaier
Journal:  Clin Chem Lab Med       Date:  2020-08-27       Impact factor: 3.694

Review 2.  SARS-CoV-2 vaccines in development.

Authors:  Florian Krammer
Journal:  Nature       Date:  2020-09-23       Impact factor: 49.962

3.  Brief clinical evaluation of six high-throughput SARS-CoV-2 IgG antibody assays.

Authors:  Niko Kohmer; Sandra Westhaus; Cornelia Rühl; Sandra Ciesek; Holger F Rabenau
Journal:  J Clin Virol       Date:  2020-06-01       Impact factor: 3.168

4.  Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity.

Authors:  Jorge Carrillo; Nuria Izquierdo-Useros; Carlos Ávila-Nieto; Edwards Pradenas; Bonaventura Clotet; Julià Blanco
Journal:  Biochem Biophys Res Commun       Date:  2020-11-07       Impact factor: 3.575

5.  Quantification of SARS-CoV-2 antibodies with eight commercially available immunoassays.

Authors:  Lisa Weidner; Simon Gänsdorfer; Stephan Unterweger; Lukas Weseslindtner; Camilla Drexler; Maria Farcet; Volker Witt; Elisabeth Schistal; Peter Schlenke; Thomas R Kreil; Christof Jungbauer
Journal:  J Clin Virol       Date:  2020-07-06       Impact factor: 3.168

Review 6.  Laboratory testing of SARS-CoV, MERS-CoV, and SARS-CoV-2 (2019-nCoV): Current status, challenges, and countermeasures.

Authors:  Ying Yan; Le Chang; Lunan Wang
Journal:  Rev Med Virol       Date:  2020-04-17       Impact factor: 6.989

7.  Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model.

Authors:  Thomas F Rogers; Fangzhu Zhao; Deli Huang; Nathan Beutler; Alison Burns; Wan-Ting He; Oliver Limbo; Chloe Smith; Ge Song; Jordan Woehl; Linlin Yang; Robert K Abbott; Sean Callaghan; Elijah Garcia; Jonathan Hurtado; Mara Parren; Linghang Peng; Sydney Ramirez; James Ricketts; Michael J Ricciardi; Stephen A Rawlings; Nicholas C Wu; Meng Yuan; Davey M Smith; David Nemazee; John R Teijaro; James E Voss; Ian A Wilson; Raiees Andrabi; Bryan Briney; Elise Landais; Devin Sok; Joseph G Jardine; Dennis R Burton
Journal:  Science       Date:  2020-06-15       Impact factor: 47.728

8.  Evaluation of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodies.

Authors:  Kathleen G Beavis; Scott M Matushek; Ana Precy F Abeleda; Cindy Bethel; Carlissa Hunt; Stephanie Gillen; Angelica Moran; Vera Tesic
Journal:  J Clin Virol       Date:  2020-05-23       Impact factor: 3.168

9.  Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison.

Authors: 
Journal:  Lancet Infect Dis       Date:  2020-09-23       Impact factor: 25.071

10.  Prevalence and Risk Factors of Infection in the Representative COVID-19 Cohort Munich.

Authors:  Michael Pritsch; Katja Radon; Abhishek Bakuli; Ronan Le Gleut; Laura Olbrich; Jessica Michelle Guggenbüehl Noller; Elmar Saathoff; Noemi Castelletti; Mercè Garí; Peter Pütz; Yannik Schälte; Turid Frahnow; Roman Wölfel; Camilla Rothe; Michel Pletschette; Dafni Metaxa; Felix Forster; Verena Thiel; Friedrich Rieß; Maximilian Nikolaus Diefenbach; Günter Fröschl; Jan Bruger; Simon Winter; Jonathan Frese; Kerstin Puchinger; Isabel Brand; Inge Kroidl; Jan Hasenauer; Christiane Fuchs; Andreas Wieser; Michael Hoelscher
Journal:  Int J Environ Res Public Health       Date:  2021-03-30       Impact factor: 3.390

View more
  6 in total

1.  Impact of tozinameran (BNT162b2) mRNA vaccine on kidney transplant and chronic dialysis patients: 3-5 months follow-up.

Authors:  Iddo Z Ben-Dov; Yonatan Oster; Keren Tzukert; Talia Alster; Raneem Bader; Ruth Israeli; Haya Asayag; Michal Aharon; Ido Burstein; Hadas Pri-Chen; Ashraf Imam; Roy Abel; Irit Mor-Yosef Levi; Abed Khalaileh; Esther Oiknine-Djian; Aharon Bloch; Dana G Wolf; Michal Dranitzki Elhalel
Journal:  J Nephrol       Date:  2022-01-06       Impact factor: 3.902

2.  Risk of strong antibody decline in dialysis and transplant patients after SARS-CoV-2mRNA vaccination: Six months data from the observational Dia-Vacc study.

Authors:  Julian Stumpf; Jörg Schwöbel; Tom Lindner; Leona Anders; Torsten Siepmann; Claudia Karger; Jan Hüther; Heike Martin; Petra Müller; Robert Faulhaber-Walter; Torsten Langer; Holger Schirutschke; Thomas Stehr; Frank Meistring; Annegret Pietzonka; Kirsten Anding-Rost; Katja Escher; Frank Pistrosch; Jens Schewe; Harald Seidel; Kerstin Barnett; Thilo Pluntke; Simon Cerny; Alexander Paliege; Ingolf Bast; Anne Steglich; Florian Gembardt; Friederike Kessel; Hannah Kröger; Patrick Arndt; Jan Sradnick; Kerstin Frank; Anna Klimova; René Mauer; Xina Grählert; Torsten Tonn; Christian Hugo
Journal:  Lancet Reg Health Eur       Date:  2022-04-11

3.  Correlation of the Commercial Anti-SARS-CoV-2 Receptor Binding Domain Antibody Test with the Chemiluminescent Reduction Neutralizing Test and Possible Detection of Antibodies to Emerging Variants.

Authors:  Yoshitomo Morinaga; Hideki Tani; Yasushi Terasaki; Satoshi Nomura; Hitoshi Kawasuji; Takahisa Shimada; Emiko Igarashi; Yumiko Saga; Yoshihiro Yoshida; Rei Yasukochi; Makito Kaneda; Yushi Murai; Akitoshi Ueno; Yuki Miyajima; Yasutaka Fukui; Kentaro Nagaoka; Chikako Ono; Yoshiharu Matsuura; Takashi Fujimura; Yoichi Ishida; Kazunori Oishi; Yoshihiro Yamamoto
Journal:  Microbiol Spectr       Date:  2021-12-01

4.  Persistence of SARS-CoV-2 Antibodies in Vaccinated Health Care Workers Analyzed by Coronavirus Antigen Microarray.

Authors:  Sina Hosseinian; Kathleen Powers; Milind Vasudev; Anton M Palma; Rafael de Assis; Aarti Jain; Peter Horvath; Paramveer S Birring; Rana Andary; Connie Au; Brandon Chin; Ghali Khalil; Jenny Ventura; Madeleine K Luu; Cesar Figueroa; Joshua M Obiero; Emily Silzel; Rie Nakajima; William Thomas Gombrich; Algis Jasinskas; Frank Zaldivar; Sebastian Schubl; Philip L Felgner; Saahir Khan
Journal:  Front Immunol       Date:  2022-04-12       Impact factor: 8.786

5.  Anti-SARS-CoV-2 Revaccination Success in Kidney Transplant Recipients With No Initial Humoral Response Is Linked to Primary Vaccine Type.

Authors:  Julian Stumpf; Jörg Schwöbel; Claudia Karger; Holger Schirutschke; René Mauer; Anna Klimova; Torsten Tonn; Christian Hugo
Journal:  Front Med (Lausanne)       Date:  2022-07-04

6.  Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine.

Authors:  Julian Stumpf; Torsten Siepmann; Tom Lindner; Claudia Karger; Jörg Schwöbel; Leona Anders; Robert Faulhaber-Walter; Jens Schewe; Heike Martin; Holger Schirutschke; Kerstin Barnett; Jan Hüther; Petra Müller; Torsten Langer; Thilo Pluntke; Kirsten Anding-Rost; Frank Meistring; Thomas Stehr; Annegret Pietzonka; Katja Escher; Simon Cerny; Hansjörg Rothe; Frank Pistrosch; Harald Seidel; Alexander Paliege; Joachim Beige; Ingolf Bast; Anne Steglich; Florian Gembardt; Friederike Kessel; Hannah Kröger; Patrick Arndt; Jan Sradnick; Kerstin Frank; Anna Klimova; René Mauer; Xina Grählert; Moritz Anft; Arturo Blazquez-Navarro; Timm H Westhoff; Ulrik Stervbo; Torsten Tonn; Nina Babel; Christian Hugo
Journal:  Lancet Reg Health Eur       Date:  2021-07-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.